RC
FULC icon

Rangeley Capital’s Fulcrum Therapeutics FULC Stock Holding History

Rangeley Capital’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$420K Buy
+114,890
New +$699K 0.38% 71

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rangeley Capital's FULC Position: Q2 2026 in Review

Rangeley Capital opened a new position in Fulcrum Therapeutics (FULC) in Q2 2026: 114,890 shares worth $420K. The stake represents 0.38% of the portfolio and ranks #71 among its holdings.

155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Rangeley Capital held 114,890 shares of Fulcrum Therapeutics worth $420K as of Q2 2026.
  • Fulcrum Therapeutics was a new Rangeley Capital position in Q2 2026.
  • Fulcrum Therapeutics made up 0.38% of Rangeley Capital's portfolio in Q2 2026, its #71 holding.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.